公开(公告)号：US20240317705A1

公开(公告)日：2024-09-26

申请号：US18233121

申请日：2023-08-11

申请人： Novartis AG

发明人： Birgitte Langer Eriksen ,  Magnus Gustafsson ,  Charlotte Hougaard ,  Thomas Amos Jacobsen ,  Martin R. Jefson ,  Gregg F. Keaney ,  Jessica Klein ,  Janus Schreiber Larsen ,  John A. Lowe, III ,  John M. McCall ,  Dorte Strøbæk ,  Nadia Lybøl von Schoubye

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/10 ,  C07D498/08

CPC分类号： C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/10 ,  C07D498/08

摘要： Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.